Intercept Pharmaceuticals, Inc. (ICPT)
Nov 8, 2023 - ICPT was delisted (reason: acquired by Alfasigma)
19.00
0.00 (0.00%)
Inactive · Last trade price
on Nov 7, 2023
Intercept Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '23 Sep 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2013 - 2017 |
| Revenue | 317.68 | 285.71 | 260.75 | 233.97 | 252 | 179.8 | Upgrade
|
| Revenue Growth (YoY) | 14.64% | 9.57% | 11.45% | -7.16% | 40.15% | 37.30% | Upgrade
|
| Cost of Revenue | 0.63 | 0.98 | 1.21 | 2.35 | 4.21 | 2.52 | Upgrade
|
| Gross Profit | 317.05 | 284.73 | 259.55 | 231.62 | 247.79 | 177.29 | Upgrade
|
| Selling, General & Admin | 211.73 | 176.3 | 177.49 | 260.5 | 317.42 | 255.47 | Upgrade
|
| Research & Development | 160.42 | 176.64 | 182.75 | 189.03 | 242.8 | 207.3 | Upgrade
|
| Operating Expenses | 372.15 | 352.94 | 360.24 | 449.53 | 560.22 | 462.78 | Upgrade
|
| Operating Income | -55.1 | -68.22 | -100.69 | -217.91 | -312.43 | -285.49 | Upgrade
|
| Interest Expense | -10.23 | -21.39 | -54.42 | -48.05 | -41.14 | -30.52 | Upgrade
|
| Interest & Investment Income | 5.87 | 5.87 | 6.65 | 8.25 | 7.79 | 6.75 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.64 | - | - | - | 0.79 | - | Upgrade
|
| EBT Excluding Unusual Items | -51.82 | -83.73 | -148.46 | -257.72 | -344.99 | -309.27 | Upgrade
|
| Merger & Restructuring Charges | -6.26 | - | 0.28 | -11.81 | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.65 | 0.65 | -4.69 | -3.87 | 0.31 | 0.03 | Upgrade
|
| Other Unusual Items | -0.04 | -91.78 | 16.51 | - | - | - | Upgrade
|
| Pretax Income | -57.47 | -174.86 | -136.35 | -273.4 | -344.68 | -309.24 | Upgrade
|
| Earnings From Continuing Operations | -57.47 | -174.86 | -136.35 | -273.4 | -344.68 | -309.24 | Upgrade
|
| Earnings From Discontinued Operations | -4.14 | 396.67 | 44.93 | -1.48 | - | - | Upgrade
|
| Net Income | -61.61 | 221.82 | -91.43 | -274.88 | -344.68 | -309.24 | Upgrade
|
| Net Income to Common | -61.61 | 221.82 | -91.43 | -274.88 | -344.68 | -309.24 | Upgrade
|
| Shares Outstanding (Basic) | 42 | 34 | 32 | 33 | 32 | 28 | Upgrade
|
| Shares Outstanding (Diluted) | 42 | 34 | 32 | 33 | 32 | 28 | Upgrade
|
| Shares Change (YoY) | 35.22% | 6.09% | -3.26% | 4.16% | 11.21% | 13.61% | Upgrade
|
| EPS (Basic) | -1.48 | 6.56 | -2.87 | -8.34 | -10.89 | -10.86 | Upgrade
|
| EPS (Diluted) | -1.48 | 6.55 | -2.87 | -8.34 | -10.89 | -10.86 | Upgrade
|
| Free Cash Flow | -62.83 | -27.35 | -41.46 | -175.76 | -237.75 | -240.88 | Upgrade
|
| Free Cash Flow Per Share | -1.51 | -0.81 | -1.30 | -5.33 | -7.51 | -8.46 | Upgrade
|
| Gross Margin | 99.80% | 99.66% | 99.54% | 98.99% | 98.33% | 98.60% | Upgrade
|
| Operating Margin | -17.34% | -23.88% | -38.62% | -93.14% | -123.98% | -158.78% | Upgrade
|
| Profit Margin | -19.39% | 77.64% | -35.06% | -117.48% | -136.78% | -171.99% | Upgrade
|
| Free Cash Flow Margin | -19.78% | -9.57% | -15.90% | -75.12% | -94.34% | -133.97% | Upgrade
|
| EBITDA | -54.72 | -67.62 | -97.88 | -214.97 | -308.76 | -280.91 | Upgrade
|
| EBITDA Margin | -17.22% | -23.67% | -37.54% | -91.88% | -122.52% | -156.23% | Upgrade
|
| D&A For EBITDA | 0.38 | 0.59 | 2.81 | 2.94 | 3.66 | 4.58 | Upgrade
|
| EBIT | -55.1 | -68.22 | -100.69 | -217.91 | -312.43 | -285.49 | Upgrade
|
| EBIT Margin | -17.34% | -23.88% | -38.62% | -93.14% | -123.98% | -158.78% | Upgrade
|
| Revenue as Reported | 317.68 | 285.71 | 260.75 | 233.97 | 252 | 179.8 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.